Stephanie Link Buys More Zoetis: Animal Health Stock Analysis

Zoetis Investment Rationale

• 💡 Stephanie Link explains her decision to buy more Zoetis stock, noting it currently trades at a discounted multiple compared to its historical average.
• 🎯 Despite recent underperformance attributed to CEO execution, Link believes Zoetis has a strong position in a large total addressable market.
• ⚠️ She suggests potential activism if the CEO does not improve execution, highlighting the competitive landscape with Elanco and IDEX.

Zoetis vs. Elanco and IDEX

• 📊 Zoetis is trading at 19 times forward earnings, significantly below its historical average of 30 times, while Elanco, a competitor, has seen an 81% rise and now trades at 23 times forward earnings.
• 📈 The animal health market, including Zoetis, Elanco, and IDEX, is projected to reach a $100 billion total addressable market by 2035.
• 🔑 Zoetis, despite past execution issues, still holds a significant 20% market share.

Copper Stocks: Freeport and Augusta

• ⚡ Link discusses copper stocks, noting Freeport's strong performance but citing inconsistent execution as a reason for its valuation.
• 💰 Augusta is highlighted as a superior operator with strong production growth, trading at a lower multiple (11 times EBITDA) compared to Freeport.
• 📈 Both Freeport and Augusta are expected to benefit if copper prices continue to rise.

Investment Strategy and Market Trends

• 📈 Link identifies healthcare as the best-performing sector of the quarter, referencing the FDA approval of a GLP-1 pill.
• 📌 She views Zoetis's current valuation as potentially oversold, with an expectation of mean reversion and potential rewards from new product launches in 2026 and 2027.
• 🚀 The XBI (Biotech ETF) is mentioned as a favorite trade, alongside the veterinary trade, indicating a broader positive sentiment towards healthcare and biotech.